Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis–associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis–associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-22
DOI
10.1038/s41598-020-57935-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dypeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge
- (2019) I. Dicembrini et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth
- (2019) Clémence Hollande et al. NATURE IMMUNOLOGY
- Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice
- (2019) Satoko Yamashita et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease
- (2018) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- C/EBPα-dependent preneoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer
- (2018) Ashley Cast et al. HEPATOLOGY
- Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
- (2018) Toshihiro Goto et al. Scientific Reports
- Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
- (2018) Kumiko Shiba et al. Scientific Reports
- Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance
- (2018) Devram S. Ghorpade et al. NATURE
- Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition
- (2018) Elodie M. Varin et al. Cell Metabolism
- Mouse models of nonalcoholic steatohepatitis Towards optimization of their relevance to human NASH
- (2018) Geoff Farrell et al. HEPATOLOGY
- Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
- (2018) Yuya Seko et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob/ob mice
- (2017) Ken Nakamura et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice
- (2017) Hotimah Masdan Salim et al. VASCULAR PHARMACOLOGY
- DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization
- (2016) Fen Zhuge et al. DIABETES
- The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
- (2016) Elena Buzzetti et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
- (2016) Teruo Jojima et al. Diabetology & Metabolic Syndrome
- Dipeptidyl Peptidase-4 Inhibition Ameliorates Western Diet–Induced Hepatic Steatosis and Insulin Resistance Through Hepatic Lipid Remodeling and Modulation of Hepatic Mitochondrial Function
- (2015) Annayya R. Aroor et al. DIABETES
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- (2015) Paul Angulo et al. GASTROENTEROLOGY
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
- (2015) Mattias Ekstedt et al. HEPATOLOGY
- DPP4 in diabetes
- (2015) Diana Röhrborn Frontiers in Immunology
- Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis
- (2014) Miyako Tanaka et al. Nature Communications
- Activating Transcription Factor 4 Links Metabolic Stress to Interleukin-6 Expression in Macrophages
- (2013) Y. Iwasaki et al. DIABETES
- Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet
- (2013) Keizo Nakaya et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Hepatic Crown-Like Structure: A Unique Histological Feature in Non-Alcoholic Steatohepatitis in Mice and Humans
- (2013) Michiko Itoh et al. PLoS One
- Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes
- (2013) Lan He et al. Journal of Diabetes Investigation
- Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes
- (2012) Y.-S. Lee et al. DIABETOLOGIA
- Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice
- (2012) Dewei Ye et al. GUT
- Melanocortin 4 Receptor–Deficient Mice as a Novel Mouse Model of Nonalcoholic Steatohepatitis
- (2011) Michiko Itoh et al. AMERICAN JOURNAL OF PATHOLOGY
- Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice
- (2011) Timea Csak et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism
- (2011) Masayuki Miyazaki Molecular Medicine Reports
- Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea
- (2011) Yoshimasa Aso et al. Translational Research
- Diabetes and Cancer: A Consensus Report
- (2010) E. Giovannucci et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System for Nonalcoholic Fatty Liver Disease
- (2010) Ravi Juluri et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
- (2007) Carolyn et al. Frontiers in Bioscience-Landmark
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started